Digoxin
Digitalis Glycosides
Sold as LANOXIN-PG 50 MICROGRAMS/M…
- Drug class
- Digitalis Glycosides
- Availability
- Prescription only
- Routes
- Oral, Intravenous
- Markets covered
- 3
- Products on record
- 35
- FDA reports (12 mo)
- 1,555
Overview
Digoxin is an active pharmaceutical ingredient in the Digitalis Glycosides group (C01AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 24 | May 1, 2026 |
| CA Canada | Health Canada | 9 | January 27, 2026 |
| US United States | FDA | 2 | September 4, 2024 |
GBUnited Kingdom· MHRA
24 products
Uses
Cardiac failure Digoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. Its therapeutic benefit is greatest in those patients with ventricular dilatation. Digoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.
Supraventricular arrhythmias Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic atrial flutter and fibrillation.
How to take
CACanada· Health Canada
9 products
Uses
D. (Digoxin Injection) is indicated for: Congestive Heart Failure: Digoxin Injection is indicated for the treatment of mild to moderate heart failure. Digoxin Injection increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure- related hospitalizations and emergency care, while having no effect on mortality.
Where possible, Digoxin Injection should be used with a diuretic and angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Digoxin is usually continued after failure is controlled unless some known precipitating factor is corrected.
Studies have shown that withdrawal of digoxin may worsen functional status, exercise capacity, and the left ventricular ejection fraction in patients with heart failure. g. patients with unstable renal function or whose potassium levels tend to fluctuate) a cautious withdrawal of digoxin may be considered.
USUnited States· FDA
2 products
Uses
1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. 1 ) Increasing myocardial contractility in pediatric patients with heart failure. 2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults.
1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.
Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure.
3 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation.
Drug interactions
Known interactions involving Digoxin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL163630745 · revised March 13, 2026
- [2]Health Canada (DPD) · 02048264 · revised March 22, 2025
- [3]FDA DailyMed · 03612934-62f4-40… · revised September 4, 2024 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.